Overview

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Status:
Suspended
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
In the proposed study, the investigators plan to evaluate the efficacy and safety of Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
Phase:
Phase 2
Details
Lead Sponsor:
Xiangbei Welman Pharmaceutical Co., Ltd
Treatments:
Cefoperazone
Ceftazidime
Sulbactam
Sulperazone